Kymera Investor Presentation Deck

● 29 patients were treated across 5 dose levels 7 patients remain active • KYMERA Discontinuations were primarily related to disease progression and investigator discretion Two patients discontinued for adverse event Age (years) Median (min, max) KT-333 Phase 1a: Patient Demographics Sex (n, (%)) Male ECOG (n, (%)) 0 1 Prior Anti-Cancer Therapy ≥3 Dose Level 1 0.05 mg/kg (n=4) 64.5 (57, 70) 3 (75.0) 1 (25.0) 3 (75.0) 4 (100) 3 (75.0) 1 (25.0) Dose Level 2 0.1 mg/kg (n=4) Ⓒ2023 KYMERA THERAPEUTICS, INC. 63.5 (59, 74) 1 (25.0) 4 (100) 4 (100) Dose Level 3 0.2 mg/kg (n=5) 2 (50.0) 1 (25.0) 1 (25.0) 69.0 (40,76) 3 (60.0) 2 (40.0) 3 (60.0) 5 (100) Dose Levl 4 0.4 mg/kg (n=11) 66.0 (42, 81) 5 (100) 9 (81.8) 4 (36.4) 7 (63.6) 9 (81.8) Dose Level 5 0.7 mg/kg (n=5) 61.0 (30, 69) 5 (100) 3 (60.0) 2 (40.0) 7 (63.6) 3 (27.3) 4 (80.0) Tumor Type Solid Tumor+ PTCLO CTCL T-Cell LGL-L B-Cell Lymphoma Hodgkin's 1 (9.1) + = anal; appendiceal; cholangiocarcinoma; colon adenocarcinoma; colorectal (4); duodenal; endometrial; head and neck (3); ovarian, pancreatic (2), peritoneal, rectal and renal; = anaplastic T-cell lymphoma; Data cut-off: 18 October 2023 2 (40.0) Overall (N=29) 65.0 (30, 81) 2 (40.0) 1 (20.0) 21 (72.4) 10 (34.5) 19 (65.5) 25 (86.2) 19 (65.5) 1 (3.4) 5 (17.2) 2 (6.9) 1 (3.4) 1 (3.4) PAGE 27

View entire presentation